Is Your Cancer Treatment Working? Here’s How to Tell

When undergoing immunotherapy, there’s a simple, readily available blood test that could hold the answer—and your oncologist is likely already checking it: eosinophil count.

🧪 Why Eosinophils Matter:

A type of white blood cell, eosinophil levels have been shown in studies to correlate with how well immunotherapy is working.

💡 Key Insights from Recent Research:
* A study of 14 patients with Triple Negative Breast Cancer found that increases in eosinophil counts (over 300 cells per cubic mL) were statistically associated with higher complete or partial response rates to immunotherapy (specifically durvalumab + paclitaxel).

* While not statistically significant, higher eosinophil counts also correlated with improved progression-free survival and overall survival.

✨ Your ability to track the effectiveness of immunotherapy may already be at your fingertips—ask your oncologist!

👉 If you’re seeking innovation in cancer care, visit WilliamsCancerInstitute.com to schedule your FREE consultation (link in bio).

💻 Dive deeper into the science at Pre-Scribed.com with blogs that explore groundbreaking topics in cancer care.

🎙️ Don’t miss the Pre-Scribed Podcast on YouTube—check out our latest episodes featuring Dr. Jason Williams and Dr. Nathan Goodyear.

Supporting Evidence:
* Ghebeh H, Elshenawy MA, AlSayed AD, Al-Tweigeri T. Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer. Immunotherapy. 2022;14(4):189-199.

#CancerCare #Immunotherapy #Eosinophils #TripleNegativeBreastCancer #WilliamsCancerInstitute #PreScribedPodcast #IntegrativeOncology #CancerResearch #CancerInnovation #Durvalumab #CancerBreakthroughs #HealingJourney #HopeForHealing